Close Menu

financial guidance

Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.

The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.

Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.

The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

The liquid biopsy firm beat analyst estimates on the top and bottom lines and raised full-year revenue guidance to $145 to $150 million.

The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.

The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.

Within diagnostics, molecular revenues were up 11 percent year over year to $167.8 million. The firm received two new CE marks for early infant diagnosis and testing dried blood spots.

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.